{"id":50533,"date":"2022-11-07T10:02:31","date_gmt":"2022-11-07T09:02:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/"},"modified":"2022-11-07T10:02:31","modified_gmt":"2022-11-07T09:02:31","slug":"cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/","title":{"rendered":"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research"},"content":{"rendered":"<div>\n<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Cerveau Technologies, Inc. today announced a license agreement with LEXEO Therapeutics, Inc. (LEXEO), which will enable LEXEO to use Cerveau\u2019s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer\u2019s disease.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221107005421\/en\/1627049\/4\/cerveau_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221107005421\/en\/1627049\/21\/cerveau_logo.jpg\"><\/a><\/p>\n<p>\nThe collaboration is focused on using [F-18]MK-6240 as a biomarker in LEXEO\u2019s ongoing clinical study Protocol LX1001-01, an investigational gene therapy candidate for APOE4-associated Alzheimer\u2019s disease.\n<\/p>\n<p>\n\u201cCerveau is pleased to be working with LEXEO to better understand Tau PET\u2019s utilization in supporting therapeutic trials,\u201d said Rick Hiatt, Chief Executive Officer, Cerveau Technologies, Inc. \u201cThe collaboration with LEXEO is another important step forward in our strategy of expanding our international network of key academic and pharmaceutical industry collaborators in order to help fight against neurodegenerative diseases.\u201d\n<\/p>\n<p>\n<b>About Cerveau Technologies, Inc.<\/b>\n<\/p>\n<p>\nCerveau\u2019s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer\u2019s disease.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nCerveau Technologies, Inc.<br \/>\n<br \/>Rick Hiatt, 617-906-2715<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#x74;&#x6f;&#x3a;&#x52;Fh&#105;&#97;&#x74;&#x74;&#x40;&#x63;er&#118;&#101;&#97;&#x75;&#x74;&#x65;&#x63;hn&#111;&#108;&#x6f;&#x67;&#x69;&#x65;s&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#82;&#x46;&#x68;&#105;&#x61;&#x74;&#116;&#x40;&#x63;&#101;&#x72;&#x76;&#101;&#x61;&#x75;&#116;&#x65;&#x63;&#104;&#x6e;&#x6f;&#108;&#x6f;&#x67;&#105;&#x65;&#x73;&#46;&#x63;&#x6f;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Cerveau Technologies, Inc. today announced a license agreement with LEXEO Therapeutics, Inc. (LEXEO), which will enable LEXEO to use Cerveau\u2019s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50533","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON&#8211;(BUSINESS WIRE)&#8211;Cerveau Technologies, Inc. today announced a license agreement with LEXEO Therapeutics, Inc. (LEXEO), which will enable LEXEO to use Cerveau\u2019s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-07T09:02:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221107005421\/en\/1627049\/21\/cerveau_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research\",\"datePublished\":\"2022-11-07T09:02:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/\"},\"wordCount\":214,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005421\\\/en\\\/1627049\\\/21\\\/cerveau_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/\",\"name\":\"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005421\\\/en\\\/1627049\\\/21\\\/cerveau_logo.jpg\",\"datePublished\":\"2022-11-07T09:02:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005421\\\/en\\\/1627049\\\/21\\\/cerveau_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005421\\\/en\\\/1627049\\\/21\\\/cerveau_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/","og_locale":"en_US","og_type":"article","og_title":"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research - Pharma Trend","og_description":"BOSTON&#8211;(BUSINESS WIRE)&#8211;Cerveau Technologies, Inc. today announced a license agreement with LEXEO Therapeutics, Inc. (LEXEO), which will enable LEXEO to use Cerveau\u2019s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-07T09:02:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221107005421\/en\/1627049\/21\/cerveau_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research","datePublished":"2022-11-07T09:02:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/"},"wordCount":214,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221107005421\/en\/1627049\/21\/cerveau_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/","url":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/","name":"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221107005421\/en\/1627049\/21\/cerveau_logo.jpg","datePublished":"2022-11-07T09:02:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221107005421\/en\/1627049\/21\/cerveau_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221107005421\/en\/1627049\/21\/cerveau_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50533"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50533\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}